Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Krzysztof Selmaj(Medical University of Lodz), David K.B. Li(University of British Columbia), Hans-Peter Hartung(Heinrich Heine University Düsseldorf), Bernhard Hemmer(Technical University of Munich), Ludwig Kappos(University Hospital of Basel), Mark S. Freedman(University of Ottawa), Olaf Stüve(The University of Texas Southwestern Medical Center), Peter Rieckmann(Sozialstiftung Bamberg), Xavier Montalbán(Hebron University), Tjalf Ziemssen(Technische Universität Dresden), Lixin Zhang Auberson(Novartis (Switzerland)), H. Pöhlmann(Novartis (Switzerland)), François Mercier(Novartis (Switzerland)), Frank Dahlke(Novartis (Switzerland)), Erik Wallström(Novartis (Switzerland))
Cited by 233
Abstract
Related Papers
No related papers found
Powered by citation graph analysis